Drug intelligence / Profile preview

GAL501

Development stage: Preclinical
Lead developer: Galibra Neuroscience
Modality: Gene Therapies
Administration: Intravenous

Overview

GAL501 is an adeno-associated virus (AAV)-based gene therapy currently under development by Galibra Neuroscience. It is positioned within the company's pipeline for the treatment of an undisclosed neurologic condition and is presently in the discovery stage for concept validation. While specific details regarding its molecular target and mechanism of action remain proprietary, the candidate is part of a broader therapeutic strategy focused on addressing monogenic rare disorders and prevalent neurologic conditions, often through the modulation of GABA-related pathways.

Targets

SSADH (Succinate-semialdehyde dehydrogenase)

Beyond the preview

Go deeper on GAL501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAL501.

Explore the full profile